BRCA and Lynch syndrome: who to test and risk-reducing options
- Approach to a problem
Some ovarian, breast and endometrial cancers run in families. Finding the gene lets a woman act before cancer starts, and warns her relatives.
See it in 3D: Uterine tubes · Infundibulum and fimbriae · Ovaries · Body of uterus · Mammary gland lobes
What it is
BRCA1 and BRCA2 are tumour suppressor genes that repair double-strand DNA breaks by homologous recombination. An inherited faulty copy, passed on in an autosomal dominant way by mothers or fathers, raises the risk of breast and high-grade serous ovarian, tubal and peritoneal cancer, and also of pancreatic and prostate cancer and, with BRCA2, melanoma. Lynch syndrome is an inherited fault in a DNA mismatch-repair gene (MLH1, MSH2, MSH6, PMS2, or EPCAM); it raises the risk of colorectal and endometrial cancer above all, and of ovarian, stomach, small bowel, urinary tract and other cancers. Testing combines a family history, tumour tests and germline testing with genetic counselling; carriers are offered intensive screening, risk-reducing surgery and medicines, and their relatives are offered testing.
Red flags
- Any woman with epithelial ovarian, tubal or peritoneal cancer, whatever her family history: offer germline testing.
- Breast cancer at a young age, triple-negative or in both breasts, male breast cancer in the family, or relatives with ovarian, pancreatic or metastatic prostate cancer.
- An endometrial or colorectal tumour that is mismatch-repair deficient, especially at a young age.
- Several relatives on the same side with colorectal, endometrial, ovarian, stomach or urinary tract cancers, across generations.
- A known pathogenic variant in a relative: offer that specific test (cascade testing).
Step-by-step approach
- Take a three-generation family history on both sides, with cancer types and ages at diagnosis.
- Test the tumour when there is one: mismatch-repair proteins in every endometrial and colorectal cancer; BRCA testing in ovarian cancer.
- Offer genetic counselling before testing: what a result means for her, her children and her siblings, and what can be done.
- Test an affected relative first when possible, so the family's variant is found; then offer relatives that single test.
- Positive result → a plan by gene: breast imaging, timing of risk-reducing surgery, colonoscopy for Lynch, and contraception choices.
- Negative result when the family variant is known → population risk; negative with no known variant → still manage by family history.
- Variant of uncertain significance → treat as uninformative and manage by family history; it may be reclassified later.
BRCA1, BRCA2 and Lynch side by side
| Feature | BRCA1 | BRCA2 | Lynch syndrome |
|---|---|---|---|
| Broken repair system | Homologous recombination | Homologous recombination | Mismatch repair |
| Main cancers in women | Breast (often triple-negative), high-grade serous ovarian and tubal | Breast (often hormone-receptor positive), ovarian, pancreas, melanoma | Colorectal and endometrial; also ovarian, stomach, urinary tract |
| Ovarian risk | Highest; cancers start earlier | Lower than BRCA1; later onset | Raised, varies with the gene |
| Risk-reducing gynaecological surgery | Tubes and ovaries removed, typically between 35 and 40 | Tubes and ovaries removed, typically between 40 and 45 | Hysterectomy with tubes and ovaries after childbearing, timed by gene |
| Treatment clue in the tumour | PARP inhibitors | PARP inhibitors | Immunotherapy (checkpoint inhibitors) |
Keys to the differential
- High-grade serous 'ovarian' cancer usually starts in the fimbrial end of the tube, which is why risk-reducing surgery always removes the tubes as well as the ovaries.
- Screening for ovarian cancer with CA-125 and ultrasound has not been shown to reduce deaths; risk-reducing salpingo-oophorectomy is the measure that works.
- Surgery before natural menopause → abrupt oestrogen loss → hot flushes, bone loss and cardiovascular risk; carriers without breast cancer are usually offered hormone therapy until the age of natural menopause.
- Combined hormonal contraception lowers ovarian cancer risk and is an option for carriers who have not had breast cancer.
- Breast risk in carriers is managed with yearly MRI and mammography from a younger age than average, or risk-reducing mastectomy; Lynch carriers have frequent colonoscopy.
Next step / Initial management
- Refer to genetics or genetic counselling any woman with a red flag above; document the family tree.
- After a diagnosis of ovarian cancer: germline (and tumour) BRCA testing for every woman, which also guides PARP inhibitor treatment.
- Carrier: refer to a high-risk clinic for breast screening, timing of risk-reducing surgery and, in Lynch, colonoscopy.
- Offer cascade testing to first-degree relatives, men included: sons can carry and pass on the variant.
- Before surgery: discuss menopause, fertility and future pregnancy plans; offer fertility preservation if she has not completed her family.
Common traps
- No family history means no BRCA test in ovarian cancer: many carriers have no known affected relatives, so every woman with epithelial ovarian cancer is offered testing.
- Yearly CA-125 and ultrasound protect a BRCA carrier: screening has not reduced deaths, and removing the tubes and ovaries is what lowers the risk.
- A negative test clears the family: it is only reassuring when the family's own variant is known and absent; otherwise the family history still guides care.
- A variant of uncertain significance is a positive result: most are later classed as benign, so no surgery is based on one.
- Removing the ovaries is enough: the cancer usually starts in the tube, so the tubes must come out too.
Test yourself
Think of the answer, then tap the question to see it.
A 58-year-old with high-grade serous ovarian cancer has no relatives with cancer. Should she have BRCA testing?
Yes. Every woman with epithelial ovarian cancer is offered testing: many carriers have no family history, and the result guides PARP inhibitor treatment and her relatives' care.
Why does risk-reducing surgery in a BRCA carrier remove the tubes and not only the ovaries?
Most high-grade serous cancers called ovarian start in the fimbrial end of the uterine tube.
An endometrial tumour from a 44-year-old shows loss of MSH2 and MSH6 proteins. What does this suggest and what follows?
Possible Lynch syndrome: offer genetic counselling and germline testing; if confirmed, she needs colonoscopy surveillance and her relatives can be tested.
A woman's sister carries a BRCA1 variant. She tests negative for that variant. What is her ovarian risk?
About the population risk: a negative result for a known family variant is a true negative.
Elsewhere in DurgiPedia
- Hereditary cancer syndromes: the table to know
- Familial breast cancer: BRCA1, BRCA2 and others
- Hereditary colorectal cancer: FAP and Lynch syndrome
- High-grade serous carcinoma
Connections
See it in 3D5
The structures of Durgical's 3D anatomy where it is found.
In Pharmacology1
← All of obstetrics and gynaecology
Educational content; it does not replace assessment by a doctor or your institution's protocols, and it contains no doses. For heavy bleeding, a severe headache or blurred vision, a seizure, fever, strong abdominal pain or fewer baby movements, go to an emergency department at once.
Sources: BRCA1 and BRCA2 Mutations (StatPearls Publishing (NCBI Bookshelf), 2023); Hereditary Nonpolyposis Colon Cancer (Lynch Syndrome) (StatPearls Publishing (NCBI Bookshelf), 2025); Lynch syndrome (MedlinePlus Genetics (U.S. National Library of Medicine), 2024); Ovarian cancer: MedlinePlus Genetics (MedlinePlus, US National Library of Medicine, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
